Top Story

Second part of phase 2 glaucoma study approved in Bulgaria

December 17, 2014

Regulatory authorities in Bulgaria approved patient enrollment for the second cohort of a phase 2 clinical study in glaucoma, Can-Fite BioPharma and OphthaliX announced in a press release.

In the first cohort study, patients were treated with 1 mg CF101, an A3 adenosine receptor agonist that acts as a neuroprotective agent and prevents apoptosis of retinal ganglion cells, or placebo. Masked results showed that CF101 had a favorable safety profile and was well-tolerated, the release said. A previous ophthalmic study showed CF101 lowered IOP.

NovaBay enters distribution agreement with McKesson

December 17, 2014
NovaBay announced it has signed a nationwide distribution agreement for its i-Lid Cleanser with McKesson Corp. The prescription lid and lash hygiene product aids in the…

Actavis’ newly appointed senior management team effective after Allergan acquisition

December 16, 2014
Actavis announced that the company’s newly appointed management team will become effective immediately after the anticipated successful close of the Allergan…

ABB Optical agrees to match Optometry Cares donations

December 16, 2014
Optometry Cares – the American Optometric Association Foundation has announced that ABB Optical Group, in recognition of the company's 25th anniversary, will match…
CME
Postoperative Inflammation and Pain

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Video
John Hovanesian th

Omeros granted CMS pass-through reimbursement status for Omidria

October 31, 2014
The Center for Medicare and Medicaid Services has granted Omeros Corporation with transitional pass-through status for…
More »
Breaking News

Second part of phase 2 glaucoma study approved in Bulgaria

December 17, 2014
Regulatory authorities in Bulgaria approved patient enrollment for the second cohort of a phase 2 clinical study in glaucoma, Can-Fite BioPharma and…

NovaBay enters distribution agreement with McKesson

December 17, 2014
NovaBay announced it has signed a nationwide distribution agreement for its i-Lid Cleanser with McKesson Corp. The prescription lid and lash hygiene…

Actavis’ newly appointed senior management team effective after Allergan acquisition

December 16, 2014
Actavis announced that the company’s newly appointed management team will become effective immediately after the anticipated successful close…

ABB Optical agrees to match Optometry Cares donations

December 16, 2014
Optometry Cares – the American Optometric Association Foundation has announced that ABB Optical Group, in recognition of the company's 25th…
FDA News

Genentech receives FDA breakthrough therapy designation for Lucentis

December 15, 2014
The U.S. Food and Drug Administration has granted breakthrough therapy designation for Lucentis for treatment of diabetic retinopathy, according to…

Global contact lens market to reach $13.5 billion by 2019

December 15, 2014
A report from Transparency Market Research forecasts that the global contact lens market will increase by a compound annual growth rate of 10.3% from…

Alcon supports new ISO standard for contact lens disinfection testing

December 12, 2014
Alcon announced its support for the new standards advising that lens care products be evaluated in accordance with real-world conditions for…

EnChroma adds plastic eye wear lens for spectral color enhancement

December 12, 2014
EnChroma introduced a new line of eye wear centered on prescription-capable polycarbonate lenses that provide people with color vision deficiency…
Worth Building

Close of 2014 tax planning presents challenges to individuals, businesses: Part 3

December 12, 2014
In parts 1 and 2 of this column I discussed tax breaks for individuals and businesses that may be extended or reinstated retroactively by Congress…

FDA approves Lacrivera punctum plug

December 11, 2014
Lacrivera received U.S. Food and Drug Administration approval for the VeraPlug Punctal Occluder, according to a press release.The VeraPlug offers…
More Headlines »
morganatic-roan morganatic-roan